Tirzepatide Cuts Alcohol Intake by 50% in Groundbreaking Animal Study

A new study suggests tirzepatide, the drug behind the diabetes treatment Mounjaro, could help reduce alcohol dependence. Researchers at the University of Gothenburg found that the medication significantly cut alcohol intake in animal tests. The findings raise hopes for a novel approach to treating addiction, though human trials have yet to begin.

The study revealed that voluntary alcohol consumption in animal models fell by over 50% when treated with tirzepatide. Episodes of binge drinking also dropped sharply. Scientists believe the drug works by altering the brain's reward system, reducing the dopamine response triggered by alcohol.

Tirzepatide differs from existing treatments by acting on two key receptors: GIP and GLP-1. This dual action may give it a stronger effect on addictive behaviour compared to similar drugs like semaglutide. Early evidence even suggests it could induce long-term biological changes in the brain, potentially through epigenetic modifications.

Despite promising results, no formal clinical trials for alcohol dependence have been approved by regulators. As of February 2026, neither the EMA nor the FDA has listed any Phase-III studies for this use. However, the drug's existing approval for diabetes might speed up future regulatory reviews if human trials prove successful.

Tirzepatide presents a potential breakthrough in addiction treatment by combining immediate effects on cravings with possible long-term brain changes. Further research is needed before it can be prescribed for alcohol dependence. For now, the focus remains on preclinical findings and early-stage studies.